Peking University
Clinical trials sponsored by Peking University, explained in plain language.
-
Promising bile duct cancer combo trial halted early after just one patient
Disease control TerminatedThis study aimed to see if giving chemotherapy directly into the liver artery along with two immunotherapy drugs (Atezolizumab and Bevacizumab) before and after surgery could improve outcomes for people with high-risk bile duct cancer. Only one person was enrolled before the stud…
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
Liver cancer combo trial halted early: what we know
Disease control TerminatedThis study tested whether adding a stronger chemotherapy delivery method (HAIC-TACE) to a standard targeted drug (donafenib) could help control liver cancer that cannot be surgically removed. Only 18 people enrolled before the study was stopped early, so the results are not concl…
Phase: PHASE2, PHASE3 • Sponsor: Peking University • Aim: Disease control
Last updated May 26, 2026 08:28 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat gut cancers
Disease control TerminatedThis early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (CAR-T cells) to attack a protein found on certain advanced gastrointestinal tumors. The study involved 17 adults with cancers like colorectal, gastric, or pancreatic cancer tha…
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated May 14, 2026 12:02 UTC